Press Releases
Adult Malignant Glioma Therapeutics Market Size to Observe Steady Growth

, 17 April 2019 -- ##### Malignant Glioma Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

##### Malignant Glioma Therapeutics Market – Snapshot

Gliomas account for more than 70% of all primary brain tumors. Glioblastoma is the most common (65%) and most malignant type of glioma. The global ##### malignant glioma therapeutics market is characterized by an unmet medical need of improving survival rates. The market is witnessing rapid increase in novel pipeline drug candidates from major as well as emerging market players, supported by government policies to speed up the process of orphan drug approval. Hence, the global ##### malignant glioma therapeutics market was valued at US$ 1.3 Bn in 2017 and is projected to expand at a significant CAGR of 9.2% from 2018 to 2026.

Glioblastoma multiforme (GBM) is among the most difficult of tumors to treat, and despite all efforts, median overall survival remains at approximately 12 months. Malignant gliomas are included in the category of rare diseases, and the orphan drug status is granted for the drug candidates in the pipeline. The designation for orphan drug allows manufacturers to qualify for various incentives, including tax credits for qualified clinical trials along with seven years of market exclusivity upon regulatory approval.

Moreover, expedited drug discovery process due to advent of high throughput technology and TCGA, and increase in discretionary funding for cancer research have led to the rise in clinical trials against malignant gliomas. However, significant attrition rate in clinical trials and staggeringly high prices of new-generation cancer drugs are the major factors likely to restrain the global ##### malignant glioma therapeutics market during the forecast period.

Request for Sample Copy of Report @

In terms of type, the global ##### malignant glioma therapeutics market has been classified into glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and others. Glioblastoma multiforme, which accounts for 12% to 15% of all intracranial tumors and 50% to 60% of all astrocytic tumors, is likely to be the most attractive segment during the forecast period, followed by anaplastic astrocytoma.

Strong research and development focus of manufacturers, presence of significant patient population driving demand for effective therapeutics to improve the overall survival rate, and rapidly increasing pipeline of innovative novel drugs are attributed to the high growth of the segment. Based on therapy, the global market has been divided into chemotherapy, targeted drug therapy, and radiation drug therapy.

The chemotherapy segment has been categorized into temozolomide, bevacizumab, carmustine, and others. The targeted drug therapy segment has been segmented into EGFR inhibitors, other monoclonal antibodies, and others. The market is characterized by a unique mix of patent expirations in the chemotherapy segment and rise in new patent approvals for targeted drug therapies. Loss of market exclusivity post patent expiration and reduction in branded drug prices due to competition from generic brands are likely to result in stagnant growth rate of the chemotherapy segment compared to targeted drug therapy.

The targeted drug therapy segment is likely to dominate the global ##### malignant glioma therapeutics market during the forecast period. This is because the segment comprises a promising pipeline covering diverse novel techniques such as gene therapy, nucleic acid therapies, lytic viruses, stem cells, nanoparticles, and others which are able to cross the blood brain barrier and target novel inhibition points rather than focusing on the inhibition of blood vessel formation.

Request Report Brochure @

In terms of region, the global ##### malignant glioma therapeutics market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global market in 2017, accounting for over 37% share in terms of revenue. Europe was another major market for ##### malignant glioma therapeutics in 2017. Technological advancement is a major driver of the market in North America and Europe.

However, growth of the market in the near future is likely to depend on the combined prospects in technology and opportunity in the developing countries in Asia such as China, Japan, India, and South Korea. The market in Asia Pacific is anticipated to register an above average growth rate during the forecast period owing to relatively high patient population demanding affordable care and improvement in health care infrastructure in rapidly developing countries that aid the early diagnosis of malignant gliomas.

Major players operating in the global ##### malignant glioma therapeutics market include Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Arbor Pharmaceuticals, Pfizer, Inc., AbbVie, Inc., Amgen, Inc., Bristol-Myers Squibb Company, Sun Pharmaceuticals Ltd., Teva Pharmaceutical Industries Limited, and Emcure Pharmaceuticals Limited.

# # #

Submitted by hawer on Wednesday, 17 April 2019 at 10:01 PM
Category: Health Care & Medical
Related News

Coronary Stents Market: Increase in Geriatric Population to Drive Demand
Friday, 19 Apr 2019

Wearable Medical Devices Market - Rising Number of Sports and Fitness Enthusiasts to Boost the Deman
Friday, 19 Apr 2019

Catheters Market - Increasing Demand for Minimally Invasive Surgeries to Spur the Demand
Friday, 19 Apr 2019

Fragment-based Drug Discovery Market Will be Worth US$1.15 bn by 2023
Friday, 19 Apr 2019

Homeopathy Product Market is Projected to be Worth US$17,486.2 mn by 2024
Friday, 19 Apr 2019

Related Events

3rd Annual NASH Summit | April 22-25, 2019 | Boston, MA
Monday, 22 Apr 2019

Rx Drug Abuse and Heroin Summit
Monday, 22 Apr 2019

European NeoAg Summit 2019
Tuesday, 23 Apr 2019

Wednesday, 24 Apr 2019

8th Digital Marketing for Medical Devices West
Wednesday, 24 Apr 2019

Latest News SEO Agency to Boost Your Website Traffic with Latest Technology and Smart SEO Techn
Sunday, 21 Apr 2019

Four Years of Despair Book Launch
Sunday, 21 Apr 2019

Sunday, 21 Apr 2019

Infographic presenting the 6 Steps to Sell a House in Wisconsin
Sunday, 21 Apr 2019

Benefits of the Amazing Red Tea for Weight Loss in the Healthiest Way
Sunday, 21 Apr 2019

Want to get your press releases, event listings, and job ads on Scoopasia? Register now for a FREE account or login if you already have one!
Scoopasia v1.0b. Copyright © 2019
Today is Sunday, 21 April 2019

About Scoopasia | FAQ | Privacy Policy | Contact Us

Press Releases
Event Listings
Job Listings
Arts & Entertainment
Architecture & Construction
Automotive & Travel
Consumer Technology
Enterprise Technology
Food & Fashion
Government & Policy
Health Care & Medical
News & Media
Science & Research
Sports & Fitness
Login / Register
Get Scoopasia through RSS Feeds & Email Notifications!

Journalist's Toolbox
Hello journalist, welcome to Scoopasia--a powerful online resource for media information in Asia. Scoopasia has press releases and media events for every beat and industry. All content on Scoopasia is 100% FREE. You don't even need to login!

  • Scoop Line
    (Instant Information Request)
    The easiest way to ask questions and request information from the PR community.

  • Advanced Search
    Drill down, dig deep, for media information the way you want it.

  • Journalist's Resources
    Resources and tools you can't do without.

  • PR Tools
    Scoopasia Blog Search
    Search the largest handpicked collection of Asia's most prominent and influential blogs.

  • PR Bookmarks
  • Web 2.0 Bookmarks
  • Media Bookmarks

    More Coming Soon...

  • Upcoming Events
  • Palo Alto Networks: Palo Alto Networks Next Generation Firewall Hands-on Seminar
  • DOZ Live Inspirational Conference (DOZ Live)
  • 3rd Annual NASH Summit | April 22-25, 2019 | Boston, MA
  • Rx Drug Abuse and Heroin Summit
  • European NeoAg Summit 2019

  • Latest Jobs
    Sorry, there are currently no entries posted here.